Travoprost

Inquiry

Cat Number

API157283686

CAS Number

157283-68-6

For research use only. We do not supply to patients.

For pharmaceutical-grade products or other inquiries, please contact our experts.

Product Detail Description Advanced Innovations Customer Q&A

CAS Number

157283-68-6

EINECS

682-028-9

Storage

Under -20℃

Synonyms

(5Z)-7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]-1-buten-1-yl]cyclopentyl]-5-heptenoic acid 1-methyethyl ester

Molecular Formula

C26H35F3O6

Molecular Weight

500.5

Smiles

CC(C)OC(=O)CCC/C=C\C[C@H]1[C@H](C[C@H]([C@@H]1/C=C/[C@H](COC2=CC=CC(=C2)C(F)(F)F)O)O)O

Boiling Point

584.8℃

Relative Density

1.245

pKa

13.43

General Description

Travoprost is a synthetic fluorinated analog of prostaglandin F2alpha classified as an intraocular pressure-lowering agent. It is an isopropyl ester prodrug requiring corneal esterase activation.

Mechanism of Action

Travoprost is hydrolyzed by corneal esterases to the free acid, which agonizes prostaglandin FP receptors in the ciliary body. This remodels the ciliary muscle extracellular matrix, increasing uveoscleral outflow of aqueous humor.

Application

Used in the treatment of elevated intraocular pressure. Travoprost is indicated for open-angle glaucoma and ocular hypertension, typically as once-daily topical monotherapy.

Lipid DNA nanoparticles exhibit an intrinsic affinity to the ocular surface and can be loaded with travoprost by hybridizing an aptamer that binds the medication. In travoprost-loaded nanoparticles, the drug is bound by specific, non-covalent interactions, not requiring any chemical modification of the active pharmaceutical ingredient. Fluorescently labeled travoprost-loaded nanoparticles show a long-lasting adherence to the eye, up to sixty minutes after eye drop instillation. Biosafety of the nanoparticles was proved in vivo. Ex vivo and in vivo quantification of travoprost via LC-MS revealed that the nanoparticles deliver at least twice the amount of the drug at every time-point investigated compared to the pristine drug. The data successfully show the applicability of a DNA-based drug delivery system in the field of ophthalmology for the treatment of glaucoma.

Fig. 2 Preparation and characterization of travoprost-loaded nanoparticles. (Schnichels S.; et al. 2020)

References

Schnichels S, et al. Self-assembled DNA nanoparticles loaded with travoprost for glaucoma-treatment. Nanomedicine: Nanotechnology, Biology and Medicine, 2020, 29: 102260.

What distinguishes Travoprost from other prostaglandin analogs?

Travoprost demonstrates high receptor selectivity and potent uveoscleral outflow enhancement, with studies suggesting superior intraocular pressure reduction compared to latanoprost in some patients.